CRBU (Caribou Biosciences) Other Current Receivables: $2.14 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRBU Caribou Biosciences Inc CRBU
65 GF Score
Price $1.59
GF Value $1.67
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Other Current Receivables?

Caribou Biosciences CRBU +1.27% 65 Other Current Receivables is $2.14 Mil as of Mar. 2026. GuruFocus rates CRBU with a GF Score™ of 65/100 and a GF Value™ of $1.67 (Fairly Valued). The stock has 5 warning signs investors should review.

Caribou Biosciences's Other Current Receivables for the quarter that ended in Mar. 2026 was $2.14 Mil.

Caribou Biosciences's quarterly Other Current Receivables increased from Sep. 2025 ($2.69 Mil) to Dec. 2025 ($2.91 Mil) but then stayed the same from Dec. 2025 ($2.91 Mil) to Mar. 2026 ($2.14 Mil).

Caribou Biosciences's annual Other Current Receivables declined from Dec. 2023 ($3.71 Mil) to Dec. 2024 ($2.99 Mil) and declined from Dec. 2024 ($2.99 Mil) to Dec. 2025 ($2.91 Mil).

Caribou Biosciences Other Current Receivables Related Terms

Caribou Biosciences Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Other Current Receivables Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 6.97 4.46 3.71 2.99 2.91

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.65 2.71 2.69 2.91 2.14
CRBU
65GF Score
Caribou Biosciences Inc CRBU
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $2.14 Mil mean?
Caribou Biosciences (CRBU) has a Other Current Receivables of $2.14 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Other Current Receivables too high?
Caribou Biosciences' current Other Current Receivables is $2.14 Mil. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Other Current Receivables compare to SMNR and ARCT?
Caribou Biosciences' Other Current Receivables of $2.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Other Current Receivables is $2.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.67, compared to a current price of $1.59 — trading 4.8% below its estimated fair value. The current Other Current Receivables is $2.14 Mil. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Other Current Receivables is $2.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.59 is trading 4.8% below its estimated GF Value™ of $1.67. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Other Current Receivables: $2.14 Mil
  • GF Value™: $1.67 vs. price of $1.59 (4.8% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score

Get the complete analysis for CRBU

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price
$1.67
GF Value